4//SEC Filing
Burgess Michael F. 4
Accession 0001104659-21-075168
CIK 0001773427other
Filed
May 31, 8:00 PM ET
Accepted
Jun 1, 5:25 PM ET
Size
7.5 KB
Accession
0001104659-21-075168
Insider Transaction Report
Form 4
Burgess Michael F.
Head of Research & Development
Transactions
- Award
Stock Option (Right to Buy)
2021-06-01+225,000→ 225,000 totalExercise: $81.68Exp: 2031-06-01→ Common Stock (225,000 underlying) - Award
Common Stock
2021-06-01+27,500→ 27,500 total
Footnotes (2)
- [F1]Represents restricted stock awards. The restricted stock awards shall vest as follows: thirty three percent (33%) to vest on June 1, 2022, another thirty three percent (33%) to vest on June 1, 2023 and the remaining thirty four percent (34%) to vest on June 1, 2024, such that the restricted stock awards are fully vested on June 1, 2024, subject to continued service to the Company by the Reporting Person.
- [F2]This option shall vest as follows: twenty five percent (25%) on June 1, 2022, and thereafter in thirty six (36) equal monthly installments until fully vested, subject to continued service to the Company by the Reporting Person.
Documents
Issuer
SpringWorks Therapeutics, Inc.
CIK 0001773427
Entity typeother
Related Parties
1- filerCIK 0001801745
Filing Metadata
- Form type
- 4
- Filed
- May 31, 8:00 PM ET
- Accepted
- Jun 1, 5:25 PM ET
- Size
- 7.5 KB